Atlas Trials

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents

Clinical trial NCT07307235 · RECRUITING

Trial details

NCT number
NCT07307235
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Type 2 Diabetes
Start date
2025-12-13
Primary completion
2027-06-30
Enrollment
1316

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.